An effort by Sen. Elizabeth Warren (D-Mass.), other lawmakers, and advocacy groups to force the government to green-light production of a cancer drug by third-party manufacturers is meeting stiff opposition from nearly 100 interest groups and individuals.
President Joe Biden’s Health and Human Services Department should flat-out reject a plea for the government to grant so-called “march-in rights” for patents on the prostate cancer drug Xtandi, the Bayh-Dole Coalition and other individuals and interest groups said in a letter to HHS Secretary Xavier Becerra. Similar requests for march-in rights were rejected several times during the Obama administration, according to the ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.